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Background: Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere
with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-β (TGF-β) function and, to present antiangiogenic,
antiproliferative and proapoptotic properties in several solid tumor models. Based on the fact that high levels of
Vascular Endothelial Growth Factor (VEGF) and increased angiogenesis have been described in acute myeloid leukemia
and associated with disease progression, we studied the in vivo effects of HF using an Acute Promyelocytic
Leukemia (APL) mouse model.
Methods: NOD/SCID mice were transplanted with leukemic cells from hCG-PML/RARA transgenic mice (TM) and
treated with HF 150 μg/kg/day for 21 days. The leukemic infiltration and the percentage of VEGF+ cells were evaluated
by morphology and flow cytometry. The effect of HF on the gene expression of several pro- and antiangiogenic factors,
phosphorylation of SMAD2 and VEGF secretion was assessed in vitro using NB4 and HUVEC cells.
Results: HF treatment resulted in hematological remission with decreased accumulation of immature cell and lower
amounts of VEGF in BM of leukemic mice. In vitro, HF modulated gene expression of several pro- and antiangiogenic
factors, reduced VEGF secretion and phosphorylation of SMAD2, blocking TGF-β-signaling.
Conclusion: Taken together, our results demonstrate that HF inhibits SMAD2 signaling and reduces leukemia growth
and angiogenesis.
Keywords: Acute Promyelocytic Leukemia, Halofuginone, SMAD, TGF-β, VEGF, AngiogenesisBackground
Halofuginone (HF) is a low-molecular-weight quinazoli-
none alkaloid that has been demonstrated to present po-
tent antitumor effects due antiproliferative [1, 2] and
proapoptotic [3] properties. Treatment with HF impaired
proliferation and induced apoptosis of several multiple
myeloma cell lines and showed antitumor activity in a* Correspondence: emrego@hcrp.fmrp.usp.br
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creativecommons.org/publicdomain/zero/1.0/myeloma xenograft mouse model [3]. In addition, HF anti-
angiogenic properties also have been shown to contribute
to control of tumor growth [4–6]. In a rat brain tumor
model, HF treatment markedly reduced vascularization
and vessel maturation resulting in reduced tumor burden
and metastasis [6].
Angiogenesis is one of the most important mechanisms of
tumor progression [7, 8] and has been associated to devel-
opment of hematological malignancies [9]. Several studies
have reported an increase in bone marrow (BM) microvessel
density (MVD) and high VEGF (Vascular Endothelial
Growth Factor) expression in multiple myeloma [10], non-
Hodgkin lymphoma [11], and acute leukemias [12, 13].cle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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of VEGF and increased MVD were found in leukemic BM
biopsies [12] and correlated with lower rates of complete re-
mission and lower overall survival [14]. In a study analyzing
12 BM biopsies from patients with acute promyelocytic
leukemia (APL), Kini et al. [15] detected increased MVD as-
sociated with high VEGF expression. After standard treat-
ment with ATRA (all-trans retinoic acid), VEGF levels and
BM MVD were normalized. Another clinical study with 17
new cases of APL associated the efficacy of the arsenic triox-
ide treatment with its antiangiogenic effect, demonstrated
by the reduced MVD in the BM and increased survival [16].
Despite the fact that all-trans retinoic acid (ATRA) is
largely applied for the treatment of APL, the use of ATRA
alone does not achieve long-term remission [17, 18]. Thus,
associations of ATRA with chemotherapy or arsenic triox-
ide have been more successful in improve long-term sur-
vival [19]. However, these treatment regiments have limited
application for elderly patients or those with serious heart
conditions [20]. In addition, the therapy with arsenic triox-
ide is not available in several developing countries [21] and
the 10-20 % of patients treated with ATRA-chemotherapy
or ATRA-arsenic trioxide association will relapse [22, 23].
Therefore, the development of new strategies for APL ther-
apeutics is necessary and angiogenesis is a potential target
to achieve a better outcome.
The exact mechanism by which HF impairs angiogen-
esis has not yet been fully characterized. Elkin et al. [24]
reported that HF treatment led to the reduction in
metalloproteinase-2 (MMP-2) expression and inhibition
of bladder carcinoma metastasis in an animal model.
However, HF effects may not be specific to malignant tis-
sues, since the implant of silicone coated with HF resulted
in reduced expression of MMP-2, bFGF and TGF-β in nor-
mal muscle [25]. In APL the TGF-β pathway is deregulated
by the cytoplasmic PML isoform (cPML) [26] and we have
demonstrated that HF inhibited cell proliferation and in-
duced apoptosis in the APL cell line NB4 through modula-
tion of TGF-β-target genes, such as c-Myc and p21 [1]. In
addition, it is noteworthy to point out that the promoter
region of the VEGF gene contains DNA-binding sequences
for hypoxia-inducible factor 1 alpha (HIF-1α) and for the
TGF-β-signaling mediators SMADs [27, 28]. Thus, activa-
tion of TGF-β pathway may be associated with increased
VEGF expression and angiogenesis in acute leukemias.
Here we analyzed the in vivo antileukemic effect of HF and
its association with the modulation of proangiogenic and
antiangiogenic factors using APL as a bone fide example of




droxy-piperidyl)acetonyl)-(3H)-quinazolinone hydrobromide)was solubilized in lactic acid priors to dilute into phos-
phate buffer solution. In vitro ED50 was previous deter-
mined [1] in vivo doses were delineated based on previous
reports of the use of this drug in solid tumors and fibrosis
models [29–32].
Mice and leukemia transplant model
BM angiogenesis was first analyzed in leukemic hCG-
PML/RARA transgenic mice (TM). Notably, in this
transgenic model, a lethal form of leukemia that closely
resembles human APL occurs after a long pre-leukemic
phase (12–15 months) and affects only 10–15 % of the
TM [33]. To analyze in vivo effects of HF we developed
an APL transplanted model. Thus, NOD/SCID mice
aged 10 to 12 weeks were irradiated with 250 cGy and
24 hours later, 2 × 106 viable cells from leukemic hCG-
PML/RARA transgenic mice (TM) were intravenously
injected. Twenty-four hours after transplantation, NOD/
SCID mice were then submitted to daily treatment with
150 μg/kg/day HF (n = 5) or vehicle only (0.9 %
NaCl; n = 5) as an intraperitoneal injection for 21 con-
secutive days. Previous experiments were performed to
confirm leukemic infiltration in transplanted animals and
to test the efficacy and toxicity of HF. All animal experi-
ments using mice were conducted according to national
guidelines for the care and use of laboratory animals (Bra-
zilian College of Animal Experimentation) and were
approved by the institutional Animal Experimentation
Ethics Committee (protocol number 062/2008).
Cell culture
NB4 cells, a permanent cell line harboring PML-RARα t
(15;17), characterizing an APL cell line [34], was used
for in vitro assays. Briefly, cells were cultured in RPMI
1640 with 10 % fetal calf serum (FCS, Gibco, BRL, UK).
Human Umbilical Vein Endothelial Cells (HUVEC) were
maintained in EBM medium supplemented with 20 %
FCS [35]. All cells were maintained at 37 °C under 5 %
CO2.
Quantification of VEGF, angiogenin, and TGF-β
NB4 cells were treated with HF for 72 hours at doses
ranging from 25 to 100 ng/mL. VEGF, angiogenin and
TGF-β concentrations in supernatants were determinate
by CBA (Cytometric Bead Array, BD Biosciences, San
Jose, CA, USA) and/or ELISA (BD Biosciences, San Jose,
CA, USA), following manufacturer’s recommendations.
Phospho-SMAD2 (P-SMAD2) identification
The phosphorylation of SMAD2 was assessed in total
protein extracts obtained from NB4 cells treated with
50, 100, and 200 ng/mL doses of HF for 6, 12, and 24
hours. We used the PathScan® Phospho-Smad2 (Ser465/
467) Sandwich ELISA Kit (Cell Signaling, Danvers, MA,
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sorbance reason. To assess the phosphorylated protein,
TGF-β1 cytokine (Sigma-Aldrich, St. Louis, MO, USA)
was added to the culture (1ng/mL) one hour before the
ending of HF treatment.
Real time PCR and PCR array
mRNA expression was assessed by real time PCR.
Briefly, total RNA was isolated using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) and was reverse tran-
scribed using the cDNA High Capacity Archive kit
(Applied Biosystems, Foster City, CA, USA). cDNA sam-
ples were used to quantify gene expression using specific
primers and probes TaqMan® (Applied Biosystems,
Foster City, CA, USA). Gapdh was included as endogen-
ous internal control. PCR array was performed using
the angiogenesis RT2 Profiler™ PCR Arrays kit (SA
Biosciences, Frederick, MD, USA), in which each cDNA
sample was processed in a 96-well plate containing 84
angiogenesis-related genes and B2M, HPRT1, RPL13A,
ACTB, and GAPDH were included as endogenous in-
ternal controls in all plates. mRNA expression of non-
treated cells or non-leukemic mice are expressed as Fold
Change = 1. Amplification was performed in plate dupli-
cates in a 7500 Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA).
Immunohistochemistry staining for VEGF in bone marrow
sections
Vertebra samples were collected from mice, fixed and
serial 5-μm sections were prepared in paraffin. Immuno-
histochemistry was performed with primary anti-VEGF
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and anti-α-actin (for TM mice) and anti-CD34
(for transplante mice) (Becton Dickinson, San Jose, CA,
USA) at 1:500, 1:800 and 1:50, respectively. Peroxidase
activity was revealed by 3,3′-diaminobenzidine as chromo-
gen. Alpha-actin and CD34 expression was used for asses-
sing microvessel density (MVD), quantified as the number
of microvessels/mm2 after analyzing three high-power
fields (400 ×).
Analysis of the hematological responses to HF in vivo
At day 21 mice were sacrificed after being subjected to a
cardiac puncture to obtain peripheral blood [36] sam-
ples. Age-matched NOD/SCID healthy animals were
used as controls (WT; n = 3). Automated counts for
white blood cells (WBC) were performed using a T-890
Coulter cell counter (Coulter Corporation, Hialeah, FL,
USA), and differential counts were obtained from
Leishman-Wright-Giemsa-stained smears. For morpho-
logical analysis, 100 cells of PB were counted, and then
myeloid cells were classified as immature, intermediate,
or mature, according to the Bethesda criteria [37]. Bonemarrow (BM) cells were obtained by flushing of the
bone cavities and the cells were used for cytospin slide
preparation and staining with Leishman-Wright-Giemsa.
Imprint slides of the spleen were also performed to quan-
tify the hematological response to HF.
Immnunophenotyping of bone marrow cells
BM cells were characterized by immnunophenotyping
using the following combinations of mAbs: CD117-PE/
CD16/32-FITC/CD45-Per-CP; CD11b-PE/Gr-1-FITC/
CD45-PerCP. Fluorochrome-conjugated isotypic anti-
bodies were used as negative controls. All antibodies
were purchased from BD Biosciences Pharmingen (San
Diego, CA, USA). A minimum of 10,000 events/tube
were acquired with a FACScalibur flow cytometer. Viable
CD45-positive cells were gated and the percentage of each
cell subset was determined using the CellQuest software
(Becton Dickinson).
ChIP assay
NB4 cells were stimulated with Halofuginone (200 ng/
mL), TGF-β (50 ng/ml) or Halofuginone (200ng/mL) +
TGF-β (50ng/mL), for 6 hours and the chormatin im-
munoprecipitation was performed with Magna ChIP™ G
(Millipore, Billerica, MA, USA) according to the instruc-
tions of manufacturer. Briefely, the crosslink was made
with 1 % formaldehyde followed by addition of 125mM
glicine to quench unreacted formaldehyde. Samples were
then resuspended in cell lysis buffer containing Proteases
Inhibitors before addition of Nuclear Lysis Buffer. The
final lysates were sonicated to shear the genomic DNA
into around 200-1000pb fragments. ChIP assay was per-
formed on the supernatants by addition of 5 μg of each
antibody: Anti-P-Smad2 (phospho S467 - ab192191);
Anti-Smad2 + Smad3 (ab63672); Anti-HIF-1α (ab2185)
and IgG rabbit polyclonal (ab27478). Primers for Vegf
promoter region were custom designed (Additional file 1:
Table S1). Graphics show Fold enrichment over IgG anti-
bodie control for each sample and primer. Primers were
purchased from Sigma- Aldrich (St. Louis, MO, USA).
Statistical analysis
All experiments were evaluated by analysis of the variance
(ANOVA) between groups followed by the Bonferroni’s
correction post-test or Mann-Whitney unpaired t-test.
In all comparisons, a significance level of P < 0.05 was
considered to be significant. Statistical analyses were
performed using SPSS 13.0 software.
Results
Angiogenesis is aberrantly increased in the APL
transgenic mouse model
Based on the demonstration of high levels of VEGF in BM
biopsies from APL patients [15], we first investigated
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model expressing the PML/RARα fusion gene under the
control of human cathepsin gene promoter (hCG) [33,
38]. Fig. 1a and b show the immunohistochemistry ana-
lysis of VEGF expression in leukemic and control BM TM
samples. There was a striking increase in the number
VEGF positive cells in leukemic BM and, by correlating
with H&E staining (not shown), it was possible to identify
that most VEGF positive cells were leukemic blasts. In
addition, the number of microvessels/mm2 in BM sections
of leukemic TM was higher than that of controls (mean of
65.2 ± 38.44 vs. 18.25 ± 7.66 microvessels/mm2, respect-
ively). These results demonstrate that the PML-RARα TM
model reproduces the increased MVD and VEGF reported
in human APL.
Halofuginone modulates expression of genes associated
with angiogenesis
Jordan and Zeplin, showed that HF significantly reduces
the gene expression of pro-angiogenic factors in physio-
logic conditions in muscle cells [25]. In order to evaluate
the effect of HF in leukemic cells, we treated the APL
cell line NB4 and performed a screening of gene expres-
sion using the PCR array method analyzing 84 prede-
fined genes involved in angiogenesis (Additional file 2:
Table S2). Among the 40 genes whose expression was
modulated by incubation with HF at the dose of 50ng/ml
for 6 hours, 16 encoded for growth factors and receptors,
6 for cytokines, 5 for proteases inhibitors and matrix
proteins, 4 for adhesion molecules and 3 for transcrip-
tion factors. As highlighted in Fig. 2a and b the expres-
sion of most proangiogenic factors was decreased and
the antiangiogenic factors TIMP2 and CXCL10 was in-
creased at all HF concentrations. The largest differences
were noted for HIF-1α (mean of 0.48 ± 0.33 fold change),
HGF (0.12 ± 0.056), angiopoetin-1 (ANGPT-1: 0.38 ± 0.19),
angiopoetin-2 (ANGPT-2: 0.57 ± 0.16), TIMP2 (2.1 ± 0.74)
and CXCL10 (16.5 ± 5.4). HF dose dependent effect was
detected for VEGFA, TIMP2 and CXCL10.LeukControl 
A
Fig. 1 Expression of the pro-angiogenic mediator VEGF is increased in APL tr
control hCG-PML-RARα transgenic mice (TM) and hCG-PML-RARα transgenic
by VEGF-staining by immunohistochemistry and analysis of three microscopicWe next evaluate if the HF effects over gene expres-
sion would extend to endothelial cells. Interestingly,
HUVEC cells treated with the aforementioned HF con-
centrations, showed increased VEGF gene expression
(9.3 ± 3.34; at 100 ng/mL) and protein secretion (Fig. 3a
and 3b). Moreover, ANGPT-1, HIF-1α, HGF, TIMP2 and
CXCL10 did not show significant change in gene expres-
sion while ANGPT-2 showed increased expression (3.5 ±
1.02; at 200 ng/mL).
Halofuginone inhibits pro-angiogenic mediators in the
APL cell line NB4
Previously, we have demonstrated that HF at concentra-
tions higher than 75 ng/ml induced TGF-β and TGFβ-R2
protein expression in NB4 cells [1]. TGF-β-cell responses
are coordinated through SMADs phosphorylation, which
translocate to nucleus and work as transcription factors
[39]. Thus, we further analyzed the phosphorylation of
SMAD2 in NB4 cells. HF treatment for 6 and 24 hours
impaired phosphorylation of SMAD2 (Fig. 4a), which was
a dose- and time-dependent effect that lasted at least for
24 hours. Based on the fact that the promoter region of
the VEGF gene contains DNA-binding sequences for
SMADs [27, 28] and the previous report that the NB4
cells secretes high levels of VEGF [15], we evaluated the
effect of HF treatment in NB4 VEGF production. Quanti-
fication of cell-culture supernatants of NB4 cells treated
with HF for 72 hours showed that VEGF levels were
strongly reduced using HF concentration of 200 ng/mL.
(Fig. 4b). In order to verify if SMAD2 has a role as tran-
scription factor for VEGF expression in NB4 cells, we
performed a ChIP assay using antibodies for the phos-
phorylated form of SMAD2 (P-SMAD2) and for the het-
erodimer SMAD2/3. Analysis of approximately 3,700 pb
neighboring the transcription start site (TSS) of VEGF
gene showed that, NB4 stimulation with TGF-β in-
creases P-SMAD2 binding in several sites upstream and
downstream VEGF. HF treatment prior TGF-β stimula-























ansgenic mouse model. a Bone marrow (BM) samples of non-leukemic
mice at leukemia diagnosis. b Percentage of VEGF positive cells detected






















































































































Fig. 2 Gene expression of angiogenic factors is down-modulated by halofuginone. a, b NB4 cells were treated with 50, 100 or 200 ng/mL of HF
for 6 hours and mRNA expression of angiogenesis determinants was assessed by PCR array. Graphic shows genes with greater differential
expression compared to nontreated cells (Fold change = 1). Data are representative of two independent experiments (error bars, s.e.m.)
Assis et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:65 Page 5 of 11ChIP assay using anti-SMAD2/3 did not showed bind-
ing of unphosphorylated SMADs upon stimulation with
TGF-β, however the previous treatment with HF
showed increase increase in two sites (2,500 and 3,600
upstream TSS) (Fig. 4d). Similarly, HIF-1α binding was
not induced only by TGF-β stimulation, and was en-
hanced with HF treatment (Additional file 3: Figure
S1A). Anti-RNA Polimerase II was used as a control of
the ChIP assay (Additional file 3: Figure S1B), and
showed increased binding in all the sites analyzed upon
TGF-β stimulation with or without HF treatment.
Halofuginone displays an anti-leukemic effect in the
in vivo model of APL
To investigate whether the anti-angiogenic properties of
HF resulted in anti-leukemic effects in APL, we used a
transplant model of PML-RARα leukemic cells in NOD/
SCID mice. All recipients developed extensive BM andspleen infiltration, leukocytosis and succumbed of the dis-
ease within 30-40 days [1]. This strategy was necessary
due to the long latency and low penetrance of the trans-
genic model, which require the observation of a large co-
hort of TM. Therefore, recipient mice were treated with
HF i.p. for 21 days starting on Day 2 post transplant and
at the end of treatment mice were sacrificied. Treatment
with HF significantly reduced white blood cell (WBC)
counts in leukemic mice (Fig. 5a). [33]. Morphological
analysis of Leishman-Wright-Giemsa-stained slides of BM
and spleen imprints confirmed the infiltration of imma-
ture cells in leukemic animals and showed a significant re-
duction of this cell pattern in the HF-treated mice
(Fig. 5b). The immunophenotypic analysis of BM showed
that HF-treated mice had a higher percentage of more dif-
ferentiated CD11b+/Gr-1+ myeloid cells and lower of
CD117+CD16/32+ (previously defined as murine leukemic































































Fig. 3 HF effects on the angiogenic factors in endothelial cell HUVEC. a Cells were treated with 50, 100 or 200 ng/mL of HF for 24 hours and
mRNA expression of angiogenic factors was assessed by real time PCR. Graphic shows differential expression compared to non-treated cells (Fold
change = 1). b Cells were treated for 72 hours to quantify VEGF production in the supernatant. CTRL: non-treated cells. ***P < 0.0001; (one-way
ANOVA). Data are representative of two independent experiments (error bars, s.e.m.)
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tion, the reduction of leukemia burden observed with HF
treatment correlated with antiangiogenic effects. Quanti-
tative and qualitative expression of VEGF by immunohis-
tochemistry showed a reduced number of VEGF+ cells
and lower VEGF expression in BM sections from HF-
treated mice than in non-treated control (Fig. 6a). Like-
wise, in our findings with the leukemic PML-RARα TM,
most of the VEGF positive cells corresponded to imma-
ture cells (Fig. 6b). Nevertheless, the reduction of the
MVD in HF-treated mice did not reach statistical sig-
nificance (158 ± 32.5 vs. 118 ± 35 microvessels/mm2 in
controls (n = 5) and treated leukemic mice (n = 5), re-
spectively). In the other hand, PCR analysis of BM sam-
ples also showed reduction in VEGF, HIF-1α and
ANGPT-2 gene expression in HF-treated mice (Fig. 6c),
whereas ANGPT-1, HGF, TIMP2 and CXCL10 had no
change in leukemic mice (data not shown).
Discussion
Here we report that HF reduced tumor burden in an
APL mouse model as showed by the cytomorphological
and immunophenotyping analysis of the BM after 21
days of treatment. This is the first study to show that
leukemic hCG-PML/RARA TM had increased VEGF ex-
pression in BM, reinforcing that VEGF may be a medi-
ator supporting leukemogenesis [41]. Using a transplant
model of PML-RARα leukemic cells, the treatment
with HF reduced the number of VEGF+ cells and
VEGF gene expression in BM of leukemic mice.However, HF treatment did not result in a significant
reduction of MVD. This may be a consequence of
the transplant model used, which led to a massive in-
filtration of the BM with a shorter survival compared
to solid tumor models. In this regard it is worthy
pointing out that in the study by Elkin et al. the ani-
mals with bladder cancer were treated with oral HF
for 26 and 29 weeks [42].
In addition, the treatment of the endothelial cell
HUVEC with HF did not change the gene expression of
ANGPT-1, HIF-1α, TIMP2 and CXCL10, whereas in-
creased VEGF gene expression and protein secretion.
These data suggests that HF effects may present vari-
ation according to the cell type, which is in accord with
the previous demonstrated increase in VEGF production
by fibrotic liver cells from rats treated with HF [43]. Fur-
thermore, it is well established that tumor cells-derived
VEGF stimulates endothelial cells to produce VEGF [44].
Considering that the basal production of VEGF showed
by NB4 cells is over 100-fold higher, the induction of
VEGF by HF treatment in endothelial cells may not have
impact in the angiogenesis process.
In non-APL AML Schuch et al. [45] demonstrated
that VEGF administration resulted in enhanced tumor
growth and vascularization whereas treatment with a
VEGF antagonist soluble NRP-1 inhibited tumor angio-
genesis and growth in a chloroma mouse model. More-
over, these authors showed that the injection of
adenovirus encoding NRP-1 reduced the leukemic bur-
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Fig. 4 Halofuginone inhibits pro-angiogenic mediators in NB4 cells. a Phospho-SMAD2 identification assessed by ELISA in NB4 cells treated with
50 and 200 ng/mL of HF for 6 and 24 hours hours and TGF-β (1ng/mL) was added to the cultures 1 hour before. b Concentration of VEGF
determined by CBA in the supernatant of NB4 cells treated with 50 and 200 ng/mL doses of HF during 72 hours. CTRL: non-treated cells. c, d ChIP
assay using antibodies to P-Smad2 and Smad2/3. NB4 cells were treated with 200 ng/mL of HF for 6 hours, or treated with 200 ng/mL of HF for
6 hours and stimulated with TGF-β (1ng/mL) in the last hour, or only stimulated with TGF-β. Graphics showing a PCR amplification of ChIP
products using a series of primer pairs covering the upstream and downstream the transcription start site (TSS) of Vegf. Data is represented as
fold enrichment to IgG control antibody. **P < 0.001, ***P < 0.0001; (one-way ANOVA). Data are representative of two a and three b) independent
experiments (error bars, s.e.m.)
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the serum of an APL patient at diagnosis and the ex-vivo
treatment with an anti-VEGF-A reduced leukemic cell
proliferation [46]. Unfortunately, in the phase II HOVON/
SAKK AML study, the administration of the anti-VEGF
agent bevacizumab along with standard chemotherapy did
not result in better outcome in older patients [47]. Thus,
despite experimental results indicating that VEGF have a
potential therapeutic benefit, the HOVON/SAKK study
suggests that inhibition of VEGF may not be sufficient to
control angiogenesis or tumor growth.
Considering HF antiangiogenic properties, we used a
PCR array to screening angiogenic mediators in the
APL cell line NB4. Our data showed a down-regulation
mediated by HF in several pro-angiogenic factors, in-
cluding HFG, HIF-1α, ANGPT-1 and -2, whereas the
anti-angiogenic factors TIMP2 and CXCL10 were over
expressed. Indeed, HGF is a well-recognized proangiogenicmediator which inhibition reduces tumor growth and
metastasis [48], as well HIF-1α, which is associated with
poor prognosis in cancer due stimulation of VEGFR+
cells migration to the tumor [49]. Contrary, CXCL10 and
TIMP2 had they antiangiogenic potential demonstrated.
Mice with fibrosarcoma treated with CXCL10 combined
with hypothermia presented reduced tumor burden and
MVD [50], whereas the MMP2-inhibitor TIMP2, have
been recently described as important prognostic factors in
acute lymphoblastic leukemia [51]. In the leukemia mouse
model, we did observe increased gene expression of VEGF,
HIF-1α and ANGPT-2, which were significantly reduced
after HF treatment. These PCR data support that HF anti-
angiogenic effect implicates multiple targets, as demon-
strated by Jordan ans Zeplin [25], MMP-2, bFGF and TGF-
β were down-modulated by HF in physiologic conditions.
On the other hand, addition of HF to NB4 cells cul-















































































Fig. 5 Halofuginone displays an anti-leukemic effect in the in vivo model of APL. a WBC account in peripheral blood obtained non-leukemic
(control), leukemic and leukemic mice treated for 21 days with HF (Leuk-HF). b BM-cell spin and spleen imprints from control and leukemic mice.
Leishman-Wright-Giemsa staining. c Immnunophenotyping of BM cells from leukemic and leuk-HF. d CD117+CD16/32+ characterize murine
promyelocytes and e CD11b+Gr-1+ are double expressed in more differentiated cells
Assis et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:65 Page 8 of 11likewise, no differentiation was observed in BM and
blood smears of recipient mice at seven and 14 days of
HF treatment (data not shown). Therefore, we believe
that increase in differentiated cells in BM of HF treated
mice reflects the restoration of normal hematopoiesis
secondary to the significant reduction of the leukemic
infiltration. Together, our results corroborate with previous
studies reporting the anti-proliferative and proapoptotic
actions of HF in solid tumors [32, 52] and in leiomyoma
cell line [53] and with recent observations from our group
demonstrating that HF induced the blockade of cell cycle
progression at G1/S transition and apoptosis in NB4 cells
[1]. Here we showed that NB4 cells treated with HF had
SMAD2 phosphorylation abrogated indicating that the
TGF-β-signaling was inhibited, which is in agreement
with previous studies [54–56]. It is proposed that VEGFgene expression is targeted by TGF-β- signaling [57–59]
and that low concentration of TGF-β cooperate with
VEGF to stimulate epithelial cell proliferation and migra-
tion [60]. Thus, one possible explanation for the VEGF
reduction induced by HF is the inhibition of the TGF-β-
signaling. One result suggest that HF acts by decreasing
SMAD-2 phosphorylation triggered by TGF-β. However,
ChIP analysis showed that, despite reduction of SMAD
phosphorylation, HF treatment increases P-SMAD2 bind-
ing to VEGF promoter region. Importantly, it has been
demonstrated that SMAD2 is not required for VEGF gene
expression, and that SMAD3 is the potential transcription
factor linking TGF-β-signaling and VEGF [57].
It has been proposed that the PML-RARα fusion
protein, similarly to cPML interacts and co-localizes










































































Fig. 6 Antiangiogenic effects of HF in the in vivo model of APL. a Immunohistochemistry staining for VEGF in BM samples of leukemic and
leukemic mice treated for 21 days with HF (Leuk-HF). b Percentage of VEGF positive cells detected by VEGF-staining by immunohistochemistry
and analysis of three microscopic fields (400×). c mRNA expression in BM samples of leukemic and Leuk-HF mice. Doted line indicates non-leukemic
mice (Fold change = 1). *P < 0.05, **P < 0.001 (one-way ANOVA). Data summarize one representative experiment (n = 5) (error bars, sd)
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Lin et al. [26]. The authors hypothesized that PML/RARα
in the cytosol inhibits TGF-β-signaling by sequestering
cPML away from the TFβR1/SARA/SMAD2/3 complex
thus preventing the trafficking to the early endosome. This
inhibition could be further enhanced by interfering with
nuclear isoform PML4, which has been demonstrated to
transactivate TGF-β target genes. Our results showed that
NB4 cells responded to the addition of TGF-β in culture
medium with an increase of about 20-fold in SMAD2
phosphorylation. HF was capable of inhibiting TGF-β-
induced SMAD2 phosphorylation. Taken together with
our previous report that HF blocked NB4 proliferation
and reduced the leukemia burden in vivo we postulated
that despite the interference of PML/RARα with TFβR1/
SARA/SMAD2/3 complex, the TGF-β pathway remain ac-
tive in APL and contributes for leukemia progression.
Conclusion
Here we showed HF can affect multiply mechanism
and that HF treatment reduced proangiogenic factorsexpression and TGF-β-signaling in vitro, in addition to
displaying antiangiogenic and antileukemic effects in an
animal model of APL. Considering the importance of
angiogenesis and deregulation of TGF-β-signaling in
tumor progression, we propose HF as a potential new
anti-cancer drug
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